Show simple item record

dc.contributor.authorCarter, Mathew
dc.contributor.authorOrtega-Franco, Ana
dc.contributor.authorRafee, Shereen
dc.contributor.authorRussell, Philip
dc.contributor.authorHalkyard, Emma
dc.contributor.authorWallace, A.
dc.contributor.authorLindsay, Colin R
dc.contributor.authorBlackhall, Fiona H
dc.date.accessioned2021-01-06T11:15:17Z
dc.date.available2021-01-06T11:15:17Z
dc.date.issued2020en
dc.identifier.citationCarter M, Ortega-Franco A, Rafee S, Russell P, Halkyard E, Wallace A, et al. Clinical utility of targeted next generation sequencing in lung cancer. Lung Cancer. 2020;139:S64-Sen
dc.identifier.urihttp://hdl.handle.net/10541/623585
dc.description.abstractIntroduction: Somatic genotyping of single genes from tissue, cytology and plasma circulating free DNA (cfDNA) is standard of care in a subpopulation of advanced non-small cell lung cancer (NSCLC). Recent developments in Next Generation Sequencing (NGS) provide innovative opportunities to explore the broader genetic landscape of lung cancer. Here, we sought to explore the clinical utility of multigene testing beyond routine standard of care indications and assess whether results were available in clinically relevant timeframes. Methods: Between 03 July and 20 September 2019, stage III and IV patients with NSCLC and small cell lung cancer (SCLC) underwent NGS via Foundation Medicine One testing from plasma (70 gene panel) and formalin-fixed paraffin-embedded (FFPE) specimens (324 gene panel) where sufficient material was available. Blood collected in two Roche cell free DNA tubes and FFPE tissue with a minimum neoplastic cell content of 20% was sent for central testing. Results: 141 patients underwent NGS testing (113 NSCLC, 28 SCLC). 19/141 patients (13%) had both blood and FFPE tested and 123/141 (87%) had only blood tested. Results were available on 114/123 (93%) blood samples. No clinically actionable mutations were identified in 6/114 (5%) blood samples, 4/114 (4%) yielded insufficient DNA, and 3/114 (3%) failed analysis. FFPE results were available in 18/19 (95%) of patients, with one deemed insufficient for analysis. Median turnaround time was 12 calendar days for blood (range 9–19 days) and 11 for tissue (range 7–17 days). Results led to an immediate treatment change in 7/141 (5%) of patients, of whom 5 were enrolled onto a clinical trial. Cases of interest will be discussed. Conclusion: These data suggest that NGS testing can be undertaken in clinically relevant time frames yielding results in 93% of our cohort. 5% of patients were immediately linked to clinical trials, with additional patients likely to be referred at subsequent lines or treatment.en
dc.language.isoenen
dc.titleClinical utility of targeted next generation sequencing in lung canceren
dc.typeMeetings and Proceedingsen
dc.contributor.departmentThe Christie NHS Foundation Trust, Manchesteren
dc.identifier.journalLung Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record